RBC Capital raised the firm’s price target on Biohaven (BHVN) to $61 from $58 and keeps an Outperform rating on the shares. With investors looking towards 2025 catalysts, Biohaven’s troriluzole resubmission to the FDA will get more attention, given its potential to drive over $1B in U.S. sales, though with outstanding questions on the regulatory path forward, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Scholar Rock price target raised to $45 from $36 at Truist
- Scholar Rock price target raised to $50 from $40 at H.C. Wainwright
- 3 Best Stocks to Buy Now, 11/26/2024, According to Top Analysts
- Biohaven study had positive signal for obesity, says H.C. Wainwright
- Macy’s uncovers employee fraud, Summit to be acquired: Morning Buzz